A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
The US FDA has approved the first of its kind ketamine-based nasal spray which is ... According to US researchers, patients eligible for the Spravato spray include adults with depression who ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment ... “This approval gives patients and healthcare professionals the freedom to further ...
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for bumetanide nasal spray (RSQ-777 ... use outpatient therapy for patients with fluid overload.